clinical trial · NCT07232875
HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer
Jiangsu HengRui Medicine Co., Ltd.·phase3·not yet recruiting·n = 588
KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line SettingHRS-4642 + AGHRS-4642 placebo + AG
brief summary
This study investigates the first-line treatment of advanced pancreatic cancer with KRAS G12D mutation. Patients were randomized 1:1 to receive either the experimental regimen HRS-4642 plus AG or the control regimen AG alone.
started
Dec 1, 2025
primary completion
Apr 1, 2029
completion
Apr 1, 2029
last updated
Nov 18, 2025
official title
a Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial of HRS-4642 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as First-Line Therapy in Patients With Advanced or Metastatic Pancreatic Carcinoma Harboring KRAS G12D Gene Mutation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol